O-2 TWO second-line docetaxel dose-schedules in advanced non-small-cell lung cancer (NSCLC): A Spanish lung cancer group (SLCG) phase III trial

Camps, Carlos; Massutí, Bartomeu; Jiménez, Ana; Batista, Noberto; Galán, Antonio; Isla, Dolores; Blanco, R.; Carrato, Alfredo; García, C. Blanco; Rosell, Rafael

doi:10.1016/s0169-5002(03)91660-6

Cited by 15 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several randomized trials compared weekly (Wd) with three-weekly (3 wD) administration of docetaxel [26][27][28][29]; however, none of these trials had sufficient power to detect clinically relevant differences in survival. Therefore, Di Maio There was no significant difference between two groups regarding anemia, thrombocytopenia, and non-hematological toxicity; however, significantly less severe and febrile neutropenia was reported with wD group (P \ 0.00001).…”

Section: Discussionmentioning

confidence: 99%

The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Because of the high risk of neutropenia with every-3-week docetaxel dosage, weekly dosing of docetaxel has also undergone extensive evaluation. Three recent phase III trials compared the standard of docetaxel 75 mg/m 2 every 3 weeks with a weekly regimen [14][15][16]. The studies ranged in size from 220 to 316 patients, with docetaxel dosed at 33-36 mg/m 2 weekly for 6 of 8 weeks or 36 mg/m 2 weekly for 3 of 4 weeks.…”

Section: Opinion Statementmentioning

confidence: 99%

Second- and third-line treatments in non-small cell lung cancer

Kumar¹,

Wakelee²

2006

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Slow but steady progress has been made in the treatment of advanced non-small cell lung cancer. For first-line therapy, multiple chemotherapy combination therapies can extend survival and improve quality of life. And recently, for the first time ever, a noncytotoxic agent, the antivascular endothelial growth factor antibody bevacizumab, has been shown to improve survival when added to chemotherapy. Striking improvements have also been made in second-line treatment. In August 2004, only one agent was US Food and Drug Administration (FDA) approved in this setting, docetaxel, but by the beginning of 2005, two more were available, pemetrexed and erlotinib. All three of these drugs can significantly benefit patients, with 1-year survival in excess of 30%. Choosing between the three agents can be challenging, and this review focuses on the toxicity differences and predictors of response that can help guide this decision. Docetaxel and pemetrexed, both traditional intravenous cytotoxins, are excellent options for patients who have shown some response to first-line chemotherapy, but at this time, no other means exist to determine likelihood of response. When choosing between the two, pemetrexed causes significantly less neutropenia than does docetaxel, at least on the standard every-3-week regimen. With erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, there are factors that can predict for response, including little or no smoking history, and adenocarcinoma histology. Therefore, patients who fit these characteristics are good candidates for second-line erlotinib. However, the relationship between response to erlotinib and improved survival remains unclear, and several laboratory analyses that may help further, such as evaluation of EGFR gene copy number, are still under development. Although erlotinib is the only FDA-approved option currently available for third-line therapy, many patients with good performance status may benefit from third-line therapy and beyond. In addition to the approved second-line options, other single-agent chemotherapies to consider for treatment beyond second-line are gemcitabine, irinotecan, and oral topotecan. Many new drugs, including bevacizumab, ZD6474 (AstraZeneca, Wilmington, DE), sorafenib, cetuximab, paclitaxel poliglumex, epothilones, and others, alone or in combination with traditional agents, are currently undergoing investigation and hold great promise.

show abstract

“…The Spanish Lung Cancer Group conducted a phase III trial comparing second-line docetaxel administered at 36 mg/m 2 for six consecutive weeks of an 8-week cycle with docetaxel administered at 75 mg/m 2 q3w in patients with advanced or metastatic NSCLC [11]. A total of 179 patients with performance status scores ≤2 were enrolled.…”

Section: Weekly Docetaxel: Clinical Overviewmentioning

confidence: 99%

Practical Aspects of Weekly Docetaxel Administration Schedules

Hainsworth

2004

The Oncologist

View full text Add to dashboard Cite

Docetaxel (Taxotere ®; Aventis Pharmaceuticals Inc.; Bridgewater, NJ) is a highly effective chemotherapeutic agent with proven efficacy in a number of solid tumors. However, myelosuppression can be a substantial concern when docetaxel is administered every 3 weeks. Myelosuppression can be particularly problematic in older patients and those being treated with palliative intent. Weekly dosing of docetaxel has been investigated in an effort to reduce toxicity and has been identified as a safe and effective regimen in clinical trials. Weekly docetaxel is generally administered at doses ranging from 30-40 mg/m 2 /week for 6 of 8 weeks or for 3 of 4 weeks. With weekly dosing, though efficacy is comparable, myelosuppression is substantially less, and the overall tolerability profile is better than with every-3-week dosing. Fatigue is a common toxicity associated with weekly docetaxel; other adverse effects that are seen in a minority of patients include hyperlacrimation, nail toxicity, and alopecia. These side effects are dose related and can generally be managed through dose reductions or alterations in the weekly schedule. Because of the favorable tolerability profile, weekly docetaxel is under investigation in combination with other chemotherapeutic agents and with novel targeted agents in a variety of tumor types. The results of these ongoing studies will further define the place of weekly docetaxel in cancer therapy. The Oncologist 2004;9:538-545 The Oncologist 2004;9:538-545 www.TheOncologist.com

show abstract

O-2 TWO second-line docetaxel dose-schedules in advanced non-small-cell lung cancer (NSCLC): A Spanish lung cancer group (SLCG) phase III trial

Cited by 15 publications

References 0 publications

The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

Second- and third-line treatments in non-small cell lung cancer

Practical Aspects of Weekly Docetaxel Administration Schedules

Contact Info

Product

Resources

About